FDX1 and gastric cancer: Yan et al. found through screening that FDX1, LIAS, and MTF1 can serve as potential prognostic biomarkers for gastric cancer patients and provide new targets for immune targeted therapy based on bioinformatics analysis (Yan et al., 2023).